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Pulmonary arterial hypertension (PAH) can be discovered in patients who have a loss of function mutation of activin A receptor-like
type 1 (ACVRL1) gene, a bone morphogenetic protein (BMP) type 1 receptor. Additionally, ACVRL1 mutations can lead to hereditary
hemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber disease, an autosomal dominant inherited disease that
results in mucocutaneous telangiectasia and arteriovenous malformations (AVMs). Transcriptional regulator Inhibitor of DNABinding/Differentiation-3 (ID3) has been demonstrated to be involved in both PAH and HTT; however, the role of its overlapping
molecular mechanistic effects has yet to be seen. This review will focus on the existing understanding of how ID3 may contribute
to molecular involvement and perturbations thus altering both PAH and HHT outcomes. Improved understanding of how ID3
mediates these pathways will likely provide knowledge in the inhibition and regulation of these diseases through targeted therapies.

1. Introduction
Inhibitor of DNA-Binding/Differentiation-3 (ID3) is part of
the ID family of proteins (helix-loop-helix) programmed
by an instant-early gene responsive to oxidative stress and
mitogenic indicators. Known as a transcriptional regulator
that prevents stem cell differentiation and promotes cell
cycle progression, ID3 has also been demonstrated to exhibit
overlapping function as a gene knockout dependent on
cellular context [1, 2]. With regard to the vasculature, ID3 is
important in embryonic vasculogenesis as well as endothelial
cell activation [1, 3, 4]. Given that these functions are
observed in endothelial cells from diseased vasculature [5],
ID3 may mediate pulmonary dysfunction often found in
individuals with cardiopulmonary disease such as pulmonary
arterial hypertension (PAH), hereditary hemorrhagic telangiectasia (HHT), and atherosclerosis [6–10]. Furthermore,
ID3 has been demonstrated to be a downstream target
of the TGF𝛽/BMP7 signaling pathway, which has been
known to play a significant role in various cellular processes
such as migration, apoptosis, and proliferation alongside

the processes of angiogenesis using two pathways: ALK5SMAD2/3 pathway and ALK1-SMAD1/5/8 pathway, important processes/pathways involved in PAH and HHT [11–14].
An enhanced understanding of interaction between ID3 and
overlapping molecular mechanisms that can be mediated in
PAH and HHT is essential in strengthening our complete
understanding of how transcriptional regulators such as ID3
can modify PAH and HHT outcomes. Additional study in
these particular areas may show both more effective or
innovative therapeutic modalities and provide strategies for
the future.

2. Inhibitor of
DNA-Binding/Differentiation-3 (ID3)
ID3 is part of a family of proteins (ID1, ID2, ID3, ID4). The
ID family shares a widespread amino acid homology within
their domain (helix-loop-helix; 69-78%) [2, 15]. Studies have
shown that in genetically engineered mice, the significance of
id3 in embryonic cell differentiation and development [16].
In dissimilarity, id1-id3 knockout mice have demonstrated
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neuronal differentiation, irregular vascularization of the
brain, and cardiac deficiencies [17, 18] that were embryonically fatal. Reports indicate that ID3 is greatly expressed in
embryonic tissue however decreases as cells differentiate [2].
The expression of ID3 in adult tissues suggests a particular
context and inclines to be at its peak in undifferentiated
and proliferating cells. ID3 expression has been described
as being stimulated by different stimuli in various cell types
[19].
ID3 was originally recognized as a serum inducible
instant-early gene in fibroblasts of mice that peak transcriptionally at 1 hour [20, 21]. ID3 expression consequently has
also been described to be biphasic with leading stimulus
at 1 hour following a secondary burst of 24 hour as in
the event of tissue regeneration after injury. ID3 proteinprotein interaction occurs in mammals through the HLH
transcriptional factors E proteins, which include HEB, E22, and E12/47. TCF12, TCF3, and TCF4 genes encode these E
proteins, respectively [22]. ID3 plays an essential function in
cell proliferation through its connections with E proteins. E
proteins have been demonstrated to bind the E-box sequence
in the promoter p21Cip1 and trigger its transcription [23]. In
perspective of the cell cycle, ID3 stimulates cell cycle progression by the inhibition of p21Cip1 expression. Protein-protein
interactions particularly with ID3 and E proteins can disturb
their capability of binding gene promoters and thus block
transcriptional initiation by these factors [24]. Furthermore,
ID3 has been revealed to inhibit E proteins from stimulating
the p21Cip1 promoter in proliferating vascular cells [25].
ID3 has been indicated to control the binding of transcription factor 3 (TCF3) to the E-box motif in target gene
promoters [26]. It has been reported that TCF3 represses the
SOX2, NANOG, and OCT4 expression that contributes to cell
differentiation [20]. Previous research has displayed overexpression, which increased both SOX2 and OCT4 expression
in endothelial cells. This resulted in a population of cells
that were positive for molecular stemness signature CD133+
VEGFR3+ CD34+ [27]. These endothelial stem cells were
differentiated into neuron and smooth muscle cells. Based
on this information, ID3 maintains cells in a noncommittal
state by counteracting the repression of pluripotency factors
by TCF3.
2.1. Pulmonary Arterial Hypertension (PAH). PAH is an
infrequent but severe vascular disorder with increased pulmonary arterial pressure (PAP) as an outcome of vascular remodeling. PAH is categorized by an increased mean
PAP (of ≥ 25 mmHg at rest), increased pulmonary vascular
resistance (PVR) of > 3 Wood units, and a pulmonary
capillary wedge pressure (PAWP) ≤ 15 mmHg, given all the
gold standard measurement is a right heart catheterization
(RHC). Nonetheless, echocardiogram can additionally give
an assessment of the severity of the disease assessing right
ventricular pressure and estimating secondary signs of right
ventricle strain [28]. PAH is connected with various aspects
and conditions. Certain drugs have been linked with the
development of PAH, including methamphetamines and
anorexigens. Additionally, portal hypertension, connective
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tissue disease, and human immunodeficiency virus can result
in PAH.
Heritable PAH (HPAH) diagnosis is pertinent when
numerous genetic mutations are discovered. Bone morphogenetic protein receptor 2 (BMPR2) mutations are found
in 75% of patients in this category [29–31]. The remaining
25% of patients are additionally connected with other genetic
mutations as well. These include BMP9, SMAD3, ENG, and
ACVLR1, which are also connected with HHT [32, 33]. These
can all be found to encode for proteins that play a function
in the transforming factor-beta (TGF-𝛽) signaling pathway.
Furthermore, BMPR2 deficiency has been previously seen to
disrupt pulmonary vascular changes causing various defects
in both systemic and heart circulation [28]. BMP signaling
is tied into the pathogenesis of atherosclerosis and BMPR2
mutations appear to produce unique singular fibrovascular
lesions, affecting larger bronchial arteries. This could explain
why increased quantities of hemoptysis are seen in PAH with
BMPR2 mutations [28–30].
2.2. Hereditary Hemorrhagic Telangiectasia (HHT). HHT is
an autosomal dominant inherited disease that affects 1 in
5000 individuals worldwide. Arteriovenous malformations
(AVMs) and mucocutaneous telangiectasia are outcomes of
vascular dysplasia. AVMs can hypothetically cultivate in
every organ; however, most affected organs are the liver,
brain, and lung. These AVMs are vulnerable to hemorrhage
and rupture, which leads to major morbidity and mortality.
Pulmonary AVMs result in blood flow from the pulmonary
artery to the pulmonary vein, resulting in a decreased filtering
volume of the pulmonary capillary bed. Complications from
pulmonary AVMs therefore include paradoxal emboli and
hypoxemia. To screen for pulmonary AVMs in HHT patients,
a contrast echocardiogram can be used [34]. In order to
decrease the risk of these severe problems, patients should be
treated with an endovascular intervention that occludes the
feeding of the pulmonary AVM with vascular plugs or coils
also known as an embolization [35]. Vascular malformation
is existent in 32-78% of HHT patients. This occurs in three
various types including hepatic artery to hepatic vein, portal
vein to hepatic vein, and/or shunting from hepatic artery to
portal vein [36, 37]. Additionally, these various AVMs can
be directly involved in the vascular defects and impaired
angiogenesis observed in HHT, which can be essentially
elucidated by the breakdown of the endothelial cells [35–37].
The most essential clinical feature of HHT is epistaxis,
from which 96% of patients suffer with HHT and additionally
more than 50% before the age of 20 years old [38, 39]. A
majority of cases are caused by mutations in the ACVRL1
or ENG genes. These mutations result in decreased levels of
functional proteins of ALK1 and Endoglin due to haploinsufficiency [40]. Another disease-triggering mutation has been
found in the SMAD4 gene, which results in a grouping of
HHT and juvenile polyposis syndrome [41]. However, this
mutation is rarer compared with others and only found in
1-2% of HHT patients. Most families associated with HHT
have a distinctive mutation and more than 900 mutations
are defined [42]. Mutations that cause HHT type 1 such as
ENG are characterized by a higher frequency of cerebral and
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Figure 1: Flow chart of PH diagnosis in HHT. Abbreviations: HHT: hereditary hemorrhagic telangiectasia; PH: pulmonary hypertension;
RHC: right heart catherization; PAH: pulmonary arterial hypertension.
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Figure 2: Diagram of the BMP9 and TGF-𝛽 pathway and involved genes and proteins in PAH and HHT. Two pathways are displayed:
ALK1/SMAD1-5 and ALK5/SMAD2-3. Abbreviations: P: phosphorylation.

pulmonary AVMs, epistaxis, and mucocutaneous telangiectasia compared to ACVRL1 mutations or HHT type 2. Most
indications with HHT are progressive with age. Clinical signs
are not only in age and subtype but also variable in severity
between families with like mutations [43]. Genetic modifiers
and etiological influences are considered to elucidate this
clinical inconsistency [44]. Distinguishing between common
symptoms of HHT and HHT complicated by PAH can be
a perplexing endeavor. HHT patients frequently experience
shortness of breath, exhaustion, and exercise intolerance due
to hypoxemia and anemia resultant of pulmonary AVMs,
psychological strain of a chronic disease, and epistaxis.
Diagnostic management of PH in HHT is contingent on the

existence of the symptoms as seen in Figure 1. If a patients’
physical exam or history indicates PH, an echocardiogram
should be implemented to measure the likelihood of PH.
2.3. Molecular Mechanisms of PAH and HHT. Signaling
pathway families such as TGF-𝛽 have been considered to
play an essential role in various cellular activities such
as apoptosis, proliferation, and migration [45]. A complex
pathway, TGF-𝛽, plays an important part in the process of
angiogenesis using two signaling pathways: ALK1-Smad 1/5/8
pathway and activin receptor-like kinase 5 (ALK5)-Smad2/3
pathway as demonstrated in Figure 2 [13, 14]. When vessels
are produced, ECs migrate and proliferate. Once the wall
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of the capillary is developed, pericytes aid in stabilizing the
vessel and inhibit endothelial migration and proliferation.
This ultimately leads to vascular maturation, in which ALK5
plays significant role. Upregulation of Endoglin via ALK1
is a necessary receptor in the TGF-𝛽/BMP signaling pathway, which is specifically expressed on proliferating ECs.
Additionally, it has been established that endoglin counterbalances the steadying function of ALK5 [46, 47]. ACVRL1
and ENG mutations disturb TGF-𝛽/BMP signaling, thus
modifying pericyte recruitment and EC tubulogenesis triggering irregular capillary maturation and formation leading
to vascular hyperbranching, AVMs, and venous expansion
elucidating the irregular morphogenesis of vascular in HHT
[13, 48].
Vascular function is also regulated by ECs through
mediating the production of vasodilators, vasoconstrictors,
and both inhibition and activation of SMCs. Outcomes due
to inhibition of apoptosis of SMCs can lead to vascular
remodeling and proliferation, eventually causing PAH. This
outcome can be due to the disruption of BMP signaling and
the SMAD1,5,8 pathway, as a consequence of an ACVRL1
and BMPR2 mutation [49–51]. However, both HHT and
PAH originate in deficiencies in the ALK1/BMP9/Endoglin
pathway. A signaling complex between ALK1 and BMPR2 is
formed, which responds to BMP9 through binding with high
affinity to Endoglin and ALK1 [32, 52]. Studies have indicated
that BMP9 has been used in animal studies to treat PAH
by stimulating BMPR2 signaling. Additionally, the mutation
of BMP9 can lead to syndrome with similar characteristics
with [53–55]. Based on these lines of evidence, it may
be plausible that BMP9 may have therapeutic benefits on
HHT.
Difficulties of HHT can be furthered by heritable pulmonary arterial hypertension (HPAH); however, this is a rare
case. Various mutations such as ACVRL1 have been explained
in HPAH patients but there seems to be a predominance
of mutations in the nonactivating nondownregulating box
(NANDOR) [42]. Nevertheless, most family members of
HHT patients with HPAH will not develop HPAH, which
suggests that further environmental or genetic influences are
needed to develop HPAH characteristics [56]. Information of
this disease grouping of PAH and HHT is significant while
this particular grouping frequently leads to worse results than
PAH alone [56]. A study by Li et al. compared HHT-PAH
patients to IPAH patients, assessing their prognosis. Oneand three-year survival rates were individually 78% and 53%
for HHT-PAH patients, suggestively lower than patients with
IPAH one- and three-year survival rates at 91% and 74%
individually [56]. SMAD4 in the pathogenesis of HPAH is
not completely known. While there are no HHT connected
SMAD4 mutation carriers defined with HPAH, there are
two PAH patients in whom a mutation in the SMAD4 gene
is established [57]. Both diseases share differences between
men and women. Epidemiological data demonstrates female
predominance in several types of PAH and life expectancy
with HHT produced by an ENG mutation [58, 59]. It is
assumed that female hormones play an essential role in both
diseases; nonetheless, the particular mechanisms are not yet
completely comprehended [60–62].
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2.4. Inﬂuence of ID3 on PAH and HHT. ID proteins are
downstream targets of the BMP signaling pathway. While literature evidence is limited, influence of ID3 on both PAH an
HHT has been demonstrated as seen in Table 1 through pathways previously highlighted in this review paper. Mutations
in the BMPR2 gene, encoding the type II BMP receptor, have
been previously identified in patients with PAH, implicating
BMP signaling in PAH. BMP receptors Ib and II together
with SMAD 4,5,6, and 8 were downregulated in lungs but
not kidneys of monocrotaline (MCT) rats. Expression of
BMP/SMAD target genes ID1 & ID3 and SMAD1 phosphorylation was decreased. Induction of the BMP/SMADresponsive component of the ID1 promoter, SMAD expression, and SMAD1 phosphorylation demonstrated a decrease
in pulmonary arterial smooth muscle cells (PASMCs) from
MCT-inoculated rats. Due to impaired BMP/SMAD signaling, the PASMCs from the MCT-inoculated rats were defiant
to apoptosis stimulated by BMP7 and BMP4. Based on this
information, the results show how ID3 is involved in BMP
signaling, which transpires in the pathogenesis of human
PAH [63]. Furthermore, Lowery et al. evaluated pulmonary
expression of ID proteins in a mouse model of a hypoxiainduced PH. Results showed selective induction of ID1 and
ID3 expression in hypoxic VSMCs in vivo. Additionally,
expression of ID1 and ID3 are increased by hypoxia in
cultured pulmonary VSMCs in BMP-dependent nature. PH
response to chronic hypoxia is dim between wild type and id1
null mice. This is connected with a compensatory rise in ID3
but not ID2 expression in pulmonary VSMCs of id1 null mice.
Taken together, these findings indicate that expression of ID1
and ID3 is regulated in a BMP-dependent fashion in hypoxic
pulmonary VSMCs. ID1 and ID3 may also play compliant
function in regulating BMP-contingent VSMC response to
chronic hypoxia [64].
Yang et al. investigated ID protein expression in human
PASMCs by immunoblotting and real-time PCR. ID3 expression in pulmonary vessels was investigated in BMPRII mutant mice and in patients with heritable PAH.
BMP4 and BMP induced mRNA expression of ID1,
ID2, and ID3. The BMP-stimulated initiation of ID1
and ID3 was evidently decreased in BMPR-II mutant
PASMCs and in control PASMCs succeeding siRNA
suppression of BMPR-II. Pulmonary arteries in bmpr2
mutant mice and patients with heritable PAH exhibited
decreased levels of ID3 compared with control subjects.
Furthermore, lentiviral ID3 overexpression reduced cell
cycle progression and inhibited proliferation of PASMCs.
Based on these lines of evidence, ID3 is one of the ID
proteins considered as critical downstream effector of
BMP signaling in PASMCs. Both ID1 and ID3 regulate
proliferation of PASMCs via cell cycle inhibition, which may
be intensified by inflammatory stimuli [9]. Gender also plays
a large role in PAH development. Women develop PAH more
frequently than men. Female non-PAH heritable PASMCs
presented decreased messenger RNA and protein expression
of BMPR2, SMAD1, ID1, and ID3. Phospho-SMAD1,5,8 and
ID protein induction by BMP4 was also decreased in female heritable PASMCs. In male heritable PASMCs,
estrogen decreased messenger RNA and expression. The
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Table 1: ID3 and PAH & HHT described in the scientific literature.
ID3 Associated Study Title
Dysregulated bone morphogenetic protein
signaling in monocrotaline-induced
pulmonary arterial hypertension
ID family protein expression and regulation
in hypoxic pulmonary hypertension
BMP induces EphrinB2 expression in
endothelial cells through an
Alk1-BMPRII/ActRII-ID1/ID3-dependent
pathway: implications for hereditary
hemorrhagic telangiectasia type II
Id proteins are critical downstream
effectors of BMP signaling in human
pulmonary arterial smooth muscle cells
Sex affects bone morphogenetic
protein type II receptor signaling in
pulmonary artery smooth muscle
cells
ID3 contributes to the acquisition of
molecular stem cell-like signature in
microvascular endothelial cells: its
implication for understanding microvascular
diseases
ID3, estrogenic chemicals, and the
pathogenesis of tumor-like proliferative
vascular lesions
The role of ID3 and PCB153 in the
hyperproliferation and dysregulation of
lung endothelial cells

Authors
Morty et al.

Year
2007

Disease
PAH

Lowery et al.

2010

PH

Kim et al.

2012

HHT

Yang et al.

2013

PAH

Mair et al.

2015

PAH

Das et al.

2015

IPAH, PAH

Avecilla V.

2017

PAH, HHT

Doke MA.

2018

PAH

estrogen metabolite 4-hydroxyestradiol decreased phosphoSMAD1,5,8 and ID expression in female heritable PASMCs
while increasing these in males corresponding with a
decreased proliferative effect in male heritable PASMCs
[10].
ID3 has also been shown to transcriptionally reprogram
lung endothelial cells via induction of proliferation and environmental toxicant PCB153. Committed ectopic ID3 expression in lung endothelial cells contributed to endothelialmesenchymal transition, cell migration, and cell proliferation. Using an established method to measure aberrant
hyperproliferation of endothelial cells in PAH patients, Doke
showed that established ectopic expression of ID3 increased
the size and number of vascular spheres. Using ChIPSequence and RNA-Sequence methodology, ID3 is shown to
be a part of a more general mechanism of transcriptional
regulation. The ChIP-Sequence data showed that an important preference of ID3 binding to motifs connected with
transcription factors: BC11A, PRDM1, SMAD4, FOXJ3, IRF4
ZBTB6, GATA1, IRF1, and STAT2 [65]. Additionally both
PAH and HHT have been understood to be involved with
ID3 in a vascular remodeling and dysfunction capacity. Gene
expression and machine learning analysis exhibited ID3 as
candidate target genes in PAH and HHT tissue and blood

samples. ID3 and candidate target genes including ABCB6,
ACP1, BYSL, CAD, CDH15, DCBLD2, DHRS3, DNMT1,
ID3, MCM4, and NDUFA7 were shown to be essential to
various vascular remodeling pathways such as focal adhesion,
oxidative phosphorylation, and cell cycle [66]. Lastly, using
an angiogenesis model, Kim et al. found that ALK1 ligand
BMP9 induces EPHRINB2 in an in vitro model of HHT
type 2. BMP9 stimulates both ID1 and ID3, which are both
essential for full initiation of EPHRINB2. Loss of EPHRINB2
and ALK1 caused an increased arterial-venous anastomosis, while loss of ALK1 not EPHRINB2 demonstrates an
increased expression of VEGFR2 and development. It is also
shown that BMP9 blocks EC development and is reliant on
BMPRII/ACTRII, ID1/ID3, and ALK1. Taken together, loss
of ALK1 blocks BMP9 signaling which results in decreased
expression of EPHRINB2, misregulated EC development and
anastomosis, and heightened VEGFR2 expression [8]. Based
on the scientific evidence that links ID3 with both PAH
and HHT, a schematic representation can be understood
of how ID3 can influence these disease outcomes from a
mechanistic approach as summarized in Figure 3. Additional
research is necessary in order to completely reveal how these
molecular communications between ID3 and PAH/HHT
pathways impact these disease results.
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Figure 3: Diagram of how transcriptional regulator ID3 affects various pathways in HHT and PAH. Pathways included are ALK1/SMAD1-5,
ALK/SMAD2-3, NOTCH, EPHRINB2–VEGFR2, and ALK1/ACTR2 via BMP or TGF-𝛽 signaling.

3. Conclusion
Based on the existing literature, ID3 has shown to be
connected with both PAH and HHT. Various studies have
reported individual associations between ID3-PAH and ID3HHT, respectively; however, the combination of all three is
rare but may have strong implications on their outcomes.
ID3 is a transcriptional regulator seen to be essential in
the promotion of cell cycle progression, endothelial cell
activation, and embryonic vasculogenesis. Both diseases can
be a result of mutations affecting various signaling pathways
such as TGF-𝛽 and BMP, vital for processes such as angiogenesis. Clinical indicators may not be specific but primary
diagnosis is significant for the applicable treatment and
prognosis. Thus, the overall understanding of the interactions
between ID3 and these diseases is critical to the healthcare and scientific community working with PAH or HHT
patients.
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